Law enforcement experiences with gabapentin: non-medical use, diversion, and state controlled substances laws

References

• Baird, C. R., Fox, P., & Colvin, L. A. (2014). Gabapentinoid abuse in order to potentiate the effect of methadone: A survey among substance misusers. European Addiction Research, 20(3), 115–118. https://doi.org/10.1159/000355268
   PubMed Web of Science ®Google Scholar
• Bastiaens, L., Galus, J., & Mazur, C. (2016). Abuse of gabapentin is associated with opioid addictions. Psychiatric Quarterly, 87(4), 763–767. https://doi.org/10.1007/s11126-016-9421-7
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., & Kurtz, S. P. (2021). Descriptions of gabapentin misuse and associated behaviors among a sample of opioid (mis) users in South Florida. Journal of Psychoactive Drugs, 53(1), 47–54. https://doi.org/10.1080/02791072.2020.1802087
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., Kurtz, S. P., Cicero, T. J., & Havens, J. R. (2019). An ethnographic decision model of the initiation of gabapentin misuse among and/or illicit opioid (mis)users. Drug and Alcohol Dependence, 204, 107554. https://doi.org/10.1016/j.drugalcdep.2019.107554
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., Kurtz, S. P., Ellis, M. S., & Cicero, T. J. (2019). Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers. Journal of Substance Abuse Treatment, 105, 1–4. https://doi.org/10.1016/j.jsat.2019.07.011
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., Kurtz, S. P., Margolin, Z. R., & Dart, R. C. (2017). Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: Diversion rates and qualitative research findings. Pharmacoepidemiology & Drug Safety, 26(9), 1083–1086. https://doi.org/10.1002/pds.4230
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., & Surratt, H. L. (2020). Factors associated with gabapentin misuse among people who inject drugs in Appalachian kentucky. Substance Use & Misuse, 55(14), 2364–2370. https://doi.org/10.1080/10826084.2020.1817082
   PubMed Web of Science ®Google Scholar
• Colorafi, K. J., & Evans, B. (2016). Qualitative descriptive methods in health science research. HERD: Health Environments Research & Design Journal, 9(4), 16–25. https://doi.org/10.1177/1937586715614171
   Web of Science ®Google Scholar
• Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartleson, B., & Green, J. L. (2015). Trends in opioid analgesic abuse and mortality in the United States. New England Journal of Medicine, 372, 241–248. https://doi.org/10.1056/NEJMsa1406143
   PubMed Web of Science ®Google Scholar
• Ellis, M. S., Buttram, M. E., & Kasper, Z. A. (2022). Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder. Drug and Alcohol Dependence, 234, 109400. https://doi.org/10.1016/j.drugalcdep.2022.109400
   PubMed Web of Science ®Google Scholar
• Evoy, K. E., Covvey, J. R., Peckham, A. M., & Reveles, K. R. (2021). Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. International Journal of Clinical Pharmacy, 43, 1055–1064. https://doi.org/10.1007/s11096-020-01217-8
   PubMed Web of Science ®Google Scholar
• Fukada, C., Kohler, J. C., Boon, H., Austin, Z., & Krahn, M. (2012). Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada, 145(6), 280–284. https://doi.org/10.3821/145.6.cpj280
   Google Scholar
• Gomes, T., Juurlink, D. N., Antoniou, T., Mamdani, M. M., Paterson, J. M., van den Brink, W., & Tsai, A. C. (2017). Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. PLoS Medicine, 14, e1002396. https://doi.org/10.1371/journal.pmed.1002396
   PubMed Web of Science ®Google Scholar
• Goodman, C. W., & Brett, A. S. (2017). Gabapentin and pregabalin for pain - is increased prescribing a cause for concern? New England Journal of Medicine, 377(5), 411–414. https://doi.org/10.1056/NEJMp1704633
   PubMed Web of Science ®Google Scholar
• Grauer, J. S., & Cramer, J. D. (2022). Association of state-imposed restrictions on gabapentin with changes in prescribing in Medicare. Journal of General Internal Medicine, 37(14), 3630–3637. https://doi.org/10.1007/s11606-021-07314-2
   PubMed Web of Science ®Google Scholar
• Hockenhull, J., Wood, D. M., & Dargan, P. I. (2022). Online availability of gabapentin and pregabalin and the impact of legal reclassification in the United Kingdom. Drugs: Education, Prevention & Policy, 30(2), 222–226. https://doi.org/10.1080/09687637.2020.1799943
   Web of Science ®Google Scholar
• Inciardi, J. A., Surratt, H. L., Kurtz, S. P., & Burke, J. J. (2006). The diversion of prescription drugs by health care workers in Cincinnati, Ohio. Substance Use and Misuse, 41(2), 255–264. https://doi.org/10.1080/10826080500391829
   PubMed Web of Science ®Google Scholar
• Ingram, D. D., & Franco, S. J. (2014). NCHS urban-rural classification scheme for counties. National Center for Health Statistics Vital Health Statistics, 2(166), 1–75. https://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf
   Google Scholar
• Johansen, M. E. (2018). Gabapentinoid use in the United States 2002 through 2015. JAMA Internal Medicine, 178(2), 292–294. https://doi.org/10.1001/jamainternmed.2017.7856
   PubMed Web of Science ®Google Scholar
• Karavolis, Z. A., Su, A. B., & Peckham, A. M. (2021). State-level response to gabapentin misuse in the United States: Implications and future direction. American Journal of Health-System Pharmacy, 79(9), e143–e148. https://doi.org/10.1093/ajhp/zxab486
   Web of Science ®Google Scholar
• Kurtz, S. P., Buttram, M. E., Margolin, Z. R., & Wogenstahl, K. (2019). The diversion of nonscheduled psychoactive prescription medications in the United States, 2002 to 2017. Pharmacoepidemiology & Drug Safety, 28(5), 700–706. https://doi.org/10.1002/pds.4771
   PubMed Web of Science ®Google Scholar
• Pauly, N. J., Delcher, C., Slavova, S., Lindahl, E., Talbert, J., & Freeman, P. R. (2020). Trends in gabapentin prescribing in a commercially insured US adult population, 2009-2016. Journal of Managed Care and Specialty Pharmacy, 26(3), 246–252. https://doi.org/10.18553/jmcp.2020.26.3.246
   PubMed Web of Science ®Google Scholar
• Peckham, A. M., Ananickal, M. J., & Sclar, D. A. (2018). Gabapentin use, abuse, and the US opioid epidemic: The case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Management and Healthcare Policy, 11, 109–116. https://doi.org/10.2147/RMHP.S168504
   PubMed Web of Science ®Google Scholar
• Reeves, R. R., & Ladner, M. E. (2014). Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine. American Journal of Psychiatry, 171(6), 691–691. https://doi.org/10.1176/appi.ajp.2014.13111526
   PubMed Web of Science ®Google Scholar
• Schalkoff, C. A., Lancaster, K. E., Gaynes, B. N., Wang, V., Pence, B. W., Miller, W. C., & Go, V. F. (2020). The opioid and related drug epidemics in rural Appalachia: A systematic review of populations affected, risk factors, and infectious diseases. Substance Abuse, 41(1), 35–69. https://doi.org/10.1080/08897077.2019.1635555
   PubMed Web of Science ®Google Scholar
• Smith, R. V., Lofwall, M. R., & Havens, J. R. (2015). Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. American Journal of Psychiatry, 172(5), 487–488. https://doi.org/10.1176/appi.ajp.2014.14101272
   PubMed Web of Science ®Google Scholar
• Stein, M. D., Kenney, S. R., Anderson, B. J., Conti, M. T., & Bailey, G. L. (2020). Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification. Journal of Substance Abuse Treatment, 110, 37–41. https://doi.org/10.1016/j.jsat.2019.12.007
   PubMed Web of Science ®Google Scholar
• Surratt, H. L., O’Grady, C., Kurtz, S. P., Stivers, Y., Cicero, T. J., Dart, R. C., & Chen, M. (2014). Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiology & Drug Safety, 23(3), 314–320. https://doi.org/10.1002/pds.3553
   PubMed Web of Science ®Google Scholar
• U. S. Drug Enforcement Administration, Diversion Control Division. (2022). NFLIS-drug special report: Gabapentin and pregabalin reported in NFLIS, 2011-2020.
   Google Scholar
• U.S. Food and Drug Administration. (2019). FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralize, Horizant) and pregabalin (Lyrica, Lyrica CR). Retrieved January 31, 2022, from https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin
   Google Scholar
• Vickers Smith, R., Boland, E. M., Young, A. M., Lofwall, M. R., Quiroz, A., Staton, M., & Havens, J. R. (2018). A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. Psychology of Addictive Behaviors, 32(1), 115. https://doi.org/10.1037/adb0000337
   PubMed Web of Science ®Google Scholar
• Wallach, J. D., & Ross, J. S. (2018). Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts. JAMA, 319(8), 776–778. https://doi.org/10.1001/jama.2017.21897
   PubMed Web of Science ®Google Scholar
• Wilens, T., Zulauf, C., Ryland, D., Carrellas, N., & Catalina-Wellington, I. (2015). Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. The American Journal on Addictions, 24(2), 173–177. https://doi.org/10.1111/ajad.12159
   PubMed Web of Science ®Google Scholar